JPRN-UMIN000011031
Completed
Phase 2
A phase II study of neoadjuvant docetaxel/cyclophosphamide (DC) followed by epirubicin/cyclophosphamide (EC) for triple-negative breast cancer - DC followed by EC as NAC PII
Tokyo Women's Medical University0 sites34 target enrollmentStarted: June 24, 2013Last updated:
Conditionsbreast cancer
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Tokyo Women's Medical University
- Enrollment
- 34
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 70years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Severe complications history of hypersensitivity reaction for important drug in this study Bilateral breast cancer Inflammatory breast cancer Pregnant or nursing women
Investigators
Similar Trials
Recruiting
Not Applicable
A phase 2 study of neoadjuvant docetaxel, oxaliplatin, S-1 in patients with unresectable locally advanced or distant metastasis limited to lymph node gastric cancerNeoplasmsKCT0006894Asan Medical Center63
Active, not recruiting
Phase 2
eoadjuvant docetaxel, oxaliplatin and S-1 therapy for large type 3 or type 4 gastric cancerGastric cancerJPRN-jRCTs051190060GOTO Masahiro46
Completed
Phase 2
Phase II study of the combination of docetaxel, cisplatin plus S-1(DCS) for advanced or recurrent gastric cancer(KDOG 0601)Gastric cancerJPRN-UMIN000001119Department of Gastroenterology, Kitasato University School of Medicine45
Not yet recruiting
Not Applicable
A phase II trial of neoadjuvant docetaxel/5-FU/cisplatin in combination with prophylactic Pegteograstim in unresectable, locally advanced nasal cavity/paranasal squamous cell carcinoma (SCC)NeoplasmsKCT0003377The Catholic University of Korea, St. Vincent's Hospital28
Completed
Phase 2
Phase II trial of neoadjuvant docetaxel + cisplatin + fluorouracil (DCF) therapy for esophageal cancerEsophageal cancerJPRN-UMIN000028252agoya University28